Physician profile
Joohee Kim
NPI 1720044647
$10,427.32
in general payments reported to CMS, 2019-2025
53 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $1,259 · 2021: $1,030 · 2022: $1,781 · 2023: $1,544 · 2024: $2,078 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,621.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,047.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,008.03 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $731.38 | 2019-2025 | Tepezza, Krystexxa, Tavneos |
| Dexcom, INC. | $557.00 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.68 | 2019-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $541.39 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $530.94 | 2019-2025 | |
| Mannkind Corporation | $319.45 | 2022-2025 | Afrezza |
| Lilly USA, LLC | $300.08 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $256.92 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $241.50 | 2022-2024 | |
| Radius Health, INC. | $240.91 | 2019-2023 | Tymlos |
| Insulet Corporation | $226.65 | 2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $221.20 | 2019-2025 | Ultomiris, Strensiq |
| Ascendis Pharma Endocrinology INC | $198.74 | 2023-2025 | Yorvipath |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $195.24 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $193.80 | 2020-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $183.70 | 2021-2023 | Tepezza |
| Travere Therapeutics, INC. | $175.31 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $164.61 | 2019 | |
| Xeris Pharmaceuticals, INC. | $162.44 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Phathom Pharmaceuticals, INC. | $159.18 | 2024 | Voquezna |
| Bigfoot Biomedical INC | $156.93 | 2022 | |
| Calliditas Therapeutics US INC. | $155.45 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $132.79 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $123.09 | 2019-2022 | |
| Akebia Therapeutics INC | $108.86 | 2020-2025 | Vafseo |
| Recordati_rare_diseases_inc. | $107.65 | 2021-2025 | Isturisa, Signifor Lar, Cystadrops |
| Aurinia Pharma U.S., INC. | $96.96 | 2023-2024 | Lupkynis |
| Medtronic Minimed, INC. | $94.11 | 2019-2020 | |
| Genzyme Corporation | $93.04 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $87.70 | 2019-2022 | |
| Nevro Corp. | $81.87 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $79.67 | 2019-2022 | |
| Corcept Therapeutics | $75.59 | 2019-2021 | |
| Glaxosmithkline, LLC. | $74.66 | 2022-2025 | Benlysta |
| Kyowa Kirin, INC. | $70.39 | 2023-2024 | Crysvita |
| Lifescan, INC. | $65.41 | 2022-2023 | |
| Amarin Pharma, INC. | $63.53 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $62.15 | 2024 | |
| Averitas Pharma INC. | $61.89 | 2025 | Qutenza |
| Scpharmaceuticals INC. | $59.67 | 2025 | |
| Medtronic, INC. | $49.93 | 2021-2023 | Ellipsys Vascular Access System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.53 | 2020-2025 | |
| Zealand Pharma US, INC. | $46.21 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $44.93 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.88 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $30.35 | 2020 | |
| Cequr Corporation | $28.37 | 2022-2023 | Cequr Simplicity |
| Vistapharm, INC. | $25.26 | 2021 | |
| Pfizer INC. | $20.83 | 2021 | |
| Cormedix INC. | $20.44 | 2024 | Defencath |
| Ionis Pharmaceuticals, INC. | $19.52 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joohee Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.